HQY vs WEX

For growth investors, HealthEquity, Inc.

(HQY) is the stronger pick with 9. 5% revenue growth year-over-year, versus 1. 2% for WEX Inc. (WEX). WEX Inc. (WEX) offers the better valuation at 17. 0x trailing P/E (7. 4x forward), making it the more compelling value choice. Analysts rate HealthEquity, Inc. (HQY) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, WEX Inc.

(WEX) is the cheapest at 17. 0x versus HealthEquity, Inc. at 34. 1x. On forward P/E, WEX Inc. is actually cheaper at 7. 4x.

Over the past 5 years, HealthEquity, Inc.

(HQY) delivered a total return of +12. 7%, compared to -26. 5% for WEX Inc. (WEX). Over 10 years, the gap is even starker: HQY returned +228. 2% versus WEX's +60. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), HealthEquity, Inc.

(HQY) is the lower-risk stock at 1. 04β versus WEX Inc. 's 1. 16β — meaning WEX is approximately 12% more volatile than HQY relative to the S&P 500. On balance sheet safety, HealthEquity, Inc. (HQY) carries a lower debt/equity ratio of 2% versus 4% for WEX Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), HealthEquity, Inc.

(HQY) is pulling ahead at 9. 5% versus 1. 2% for WEX Inc. (WEX). On earnings-per-share growth, the picture is similar: HealthEquity, Inc. grew EPS 125. 7% year-over-year, compared to 12. 9% for WEX Inc.. Over a 3-year CAGR, HQY leads at 15. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

HealthEquity, Inc.

(HQY) is the more profitable company, earning 16. 4% net margin versus 11. 4% for WEX Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: WEX leads at 25. 4% versus 24. 6% for HQY. At the gross margin level — before operating expenses — HQY leads at 69. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, WEX Inc.

(WEX) trades at 7. 4x forward P/E versus 21. 2x for HealthEquity, Inc. — 13. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HQY: 30. 8% to $109. 89.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, HealthEquity, Inc.

(HQY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 04), +228. 2% 10Y return). Both have compounded well over 10 years (HQY: +228. 2%, WEX: +60. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (HQY (Healthcare) and WEX (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: HQY is a small-cap quality compounder stock; WEX is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.